Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:11:06 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:SILO from 2023-04-27 to 2024-04-26 - 24 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-23 08:15U:SILONews ReleaseSilo Pharma Announces Positive Results for Intranasal PTSD Treatment
2024-04-10 08:11U:SILONews ReleaseSilo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic
2024-03-20 08:30U:SILONews ReleaseSilo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
2024-03-18 07:15U:SILONews ReleaseSilo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
2024-02-28 08:25U:SILONews ReleaseSilo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
2024-02-14 08:45U:SILONews ReleaseSilo Pharma ¢ € ™s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
2024-02-01 10:00U:SILONews ReleaseSilo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
2024-01-24 08:55U:SILONews ReleaseSilo Pharma Announces Positive Results in Alzheimer ¢ € ™s Disease Study
2024-01-04 08:55U:SILONews ReleaseSilo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
2023-12-28 08:25U:SILONews ReleaseSilo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
2023-11-21 08:01U:SILONews ReleaseSilo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
2023-11-08 08:11U:SILONews ReleaseSilo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
2023-10-16 08:11U:SILONews ReleaseSilo Pharma ¢ € ™s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
2023-10-11 08:35U:SILONews ReleaseSilo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
2023-09-20 08:28U:SILONews ReleaseSilo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
2023-09-12 08:50U:SILONews ReleaseSilo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
2023-08-10 08:50U:SILONews ReleaseSilo Pharma Engages Clarivate for Intellectual Property and Patent Management
2023-08-08 08:30U:SILONews ReleaseSilo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
2023-06-23 09:01U:SILONews ReleasePsychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
2023-06-21 09:00U:SILONews ReleaseSilo Pharma ¢ € ™s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
2023-06-13 08:05U:SILONews ReleaseSilo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
2023-06-02 08:50U:SILONews ReleaseSilo Pharma Announces Participation on Webull Corporate Communications Service Platform
2023-05-30 09:00U:SILONews ReleaseSilo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
2023-05-09 08:05U:SILONews ReleaseSilo Pharma ¢ € ™s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer ¢ € ™s Disease